OTCPK:AGHC

Stock Analysis Report

Executive Summary

Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Aeon Global Health has significant price volatility in the past 3 months.
  • Aeon Global Health is not covered by any analysts.

Similar Companies

Share Price & News

How has Aeon Global Health's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.4%

OTCPK:AGHC

-1.2%

US Healthcare

-0.02%

US Market


1 Year Return

-86.5%

OTCPK:AGHC

-9.4%

US Healthcare

1.6%

US Market

AGHC underperformed the Healthcare industry which returned -8.4% over the past year.

AGHC underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

AGHCIndustryMarket
7 Day-5.4%-1.2%-0.02%
30 Day0%-2.2%2.7%
90 Day-69.8%-1.5%1.4%
1 Year-86.5%-86.5%-8.0%-9.4%3.8%1.6%
3 Year-96.3%-96.3%28.7%23.5%45.2%35.8%
5 Yearn/a62.7%53.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Aeon Global Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aeon Global Health undervalued based on future cash flows and its price relative to the stock market?

0.92x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Aeon Global Health's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Aeon Global Health's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Aeon Global Health is loss making, we can't compare its value to the US Healthcare industry average.

Aeon Global Health is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aeon Global Health, we can't assess if its growth is good value.


Price Based on Value of Assets

Aeon Global Health is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Aeon Global Health expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aeon Global Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of AGHC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Aeon Global Health's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Aeon Global Health performed over the past 5 years?

-55.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aeon Global Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Aeon Global Health's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aeon Global Health's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aeon Global Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aeon Global Health has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aeon Global Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aeon Global Health's financial position?


Financial Position Analysis

Aeon Global Health's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Aeon Global Health's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Aeon Global Health's level of debt (260.6%) compared to net worth is high (greater than 40%).

Unable to establish if Aeon Global Health's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Aeon Global Health has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Aeon Global Health has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 121.4% per year.


Next Steps

Dividend

What is Aeon Global Health's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aeon Global Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aeon Global Health's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aeon Global Health has not reported any payouts.

Unable to verify if Aeon Global Health's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aeon Global Health has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aeon Global Health's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average board tenure


CEO

Sonny Roshan (55yo)

3.1yrs

Tenure

US$359,735

Compensation

Mr. Hanif A. Roshan, also known as Sonny, Founded AEON Global Health Corp. in 2010 and has been its Chief Executive Officer and interim Principal Accounting Officer since August 7, 2016 and December 06, 20 ...


CEO Compensation Analysis

Sonny's remuneration is about average for companies of similar size in United States of America.

Sonny's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

3.7yrs

Average Tenure

54.5yo

Average Age

The tenure for the Aeon Global Health board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Sonny Roshan (55yo)

    Founder

    • Tenure: 3.1yrs
    • Compensation: US$359.74k
  • Shawn Desai

    Chief Technology Officer

    • Tenure: 0yrs
  • Paul Suda

    General Counsel

    • Tenure: 0yrs
  • Armando Moncada

    Chief Medical Officer of Anatomic Pathology

    • Tenure: 1.7yrs

Board Members

  • Charles Lucas (57yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$8.03k
  • Sonny Roshan (55yo)

    Founder

    • Tenure: 3.1yrs
    • Compensation: US$359.74k
  • Varinder Rathore (47yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$5.79k
  • Mustafa Chagani (54yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$5.79k

Company Information

Aeon Global Health Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aeon Global Health Corp.
  • Ticker: AGHC
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.041m
  • Shares outstanding: 9.92m
  • Website: https://www.aeonglobalhealth.com

Number of Employees


Location

  • Aeon Global Health Corp.
  • 2225 Centennial Drive
  • Gainesville
  • Georgia
  • 30504
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGHCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2004

Biography

Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:32
End of Day Share Price2019/09/17 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.